Naprosyn (Naproxen)

Naproxen blocks the activity of cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for converting arachidonic acid into prostaglandins. By lowering prostaglandin levels, it reduces inflammation, pain signaling, and fever generation at the affected sites.

The appropriate dose of Naprosyn is determined by the prescribing healthcare professional based on the specific indication, patient age, weight, renal function and overall risk profile. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for naproxen in pregnancy and lactation are limited. It is generally avoided, especially in the third trimester, because of potential fetal cardiovascular effects. Breastfeeding mothers should consult their physician, as naproxen can be excreted in milk.

To place an order, submit an enquiry on the Naprosyn product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both naproxen and ibuprofen belong to the NSAID class and share similar mechanisms. Naproxen has a longer half‑life, allowing less frequent dosing, while ibuprofen often requires multiple daily doses. Individual response, gastrointestinal tolerance and cardiovascular risk factors influence the choice between them.

Naprosyn should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture, heat and direct sunlight, and ensure the packaging is tightly closed to maintain stability.

Naprosyn is taken orally, usually with a full glass of water. It can be taken with or without food, although taking it with food or milk may reduce gastrointestinal discomfort. Swallow tablets whole; do not crush or chew unless specifically instructed by a healthcare provider.

The most serious adverse events include gastrointestinal bleeding or ulcer perforation, serious cardiovascular events such as heart attack or stroke, severe skin reactions (e.g., Stevens‑Johnson syndrome), and acute kidney injury. Patients should be monitored closely for these complications.

Naprosyn is contraindicated in individuals with known hypersensitivity to naproxen or other NSAIDs, those with active gastrointestinal ulceration or bleeding, severe heart failure, and patients who have had a recent myocardial infarction or stroke. It should also be avoided in late pregnancy.